Postoperative Radiotherapy May Improve Survival in Incompletely Resected Lung Cancer

Share this content:
Postoperative radiotherapy associated with improved overall survival in incompletely resected NSCLC.
Postoperative radiotherapy associated with improved overall survival in incompletely resected NSCLC.

Postoperative radiotherapy is associated with improved overall survival in patients with incompletely resected stage II or III N0-2 non-small cell lung cancer (NSCLC), a new study published online ahead of print in the Journal of Clinical Oncology has shown.

For the study, researchers identified 3,395 patients with pathologic stage II or III NSCLC who had undergone a lobectomy or pneumonectomy with positive surgical margins from the National Cancer Data Base. Of those, 1,207 (35.6%) received external-beam postoperative radiotherapy at 50 to 74 Gy.

Results showed postoperative radiotherapy was associated with improved overall survival (HR = 0.80; 95% CI: 0.70, 0.92). Subset analysis demonstrated that postoperative radiotherapy improved survival across all nodal stages (N0-2).

RELATED: Radiofrequency Ablation Safe, Effective in Medically Inoperable Lung Cancer

Researchers found that age less than 60 years, earlier year of diagnosis, treatment in a nonacademic facility, lower nodal stage, decreased travel distance, and receipt of chemotherapy increased the likelihood that patients underwent postoperative radiotherapy.

The findings suggest that postoperative radiotherapy should be used in patients with incompletely resected NSCLC.

Reference

  1. Wang EH, Corso CD, Rutter CD, et al. Postoperative radiation therapy is associated with improved overall survival in incompletely resected stage II and III non-small-cell lung cancer. J Clin Oncol. 2015. [Epub ahead of print]. doi: 10.1200/JCO.2015.61.1517.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters